Chagas disease vaccine design: the search for an efficient Trypanosoma cruzi immune-mediated control.

[1]  P. Hotez,et al.  A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection , 2019, PLoS neglected tropical diseases.

[2]  I. Almeida,et al.  A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease , 2019, npj Vaccines.

[3]  E. Tenorio-Borroto,et al.  TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice. , 2019, Vaccine.

[4]  Bruce Y. Lee,et al.  The economic value of identifying and treating Chagas disease patients earlier and the impact on Trypanosoma cruzi transmission , 2018, PLoS neglected tropical diseases.

[5]  C. A. Alba Soto,et al.  IL‐10 participates in the expansion and functional activation of CD8+ T cells during acute infection with Trypanosoma cruzi , 2018, Journal of leukocyte biology.

[6]  J. J. de la Cruz,et al.  Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice , 2018, Human vaccines & immunotherapeutics.

[7]  I. Marcipar,et al.  Genetic Engineering of Lactococcus lactis Co-producing Antigen and the Mucosal Adjuvant 3′ 5′- cyclic di Adenosine Monophosphate (c-di-AMP) as a Design Strategy to Develop a Mucosal Vaccine Prototype , 2018, Front. Microbiol..

[8]  E. Malchiodi,et al.  Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine , 2018, PLoS neglected tropical diseases.

[9]  P. Hotez,et al.  Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease , 2018, Infection and Immunity.

[10]  E. Malchiodi,et al.  Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection , 2017, npj Vaccines.

[11]  S. Yusuf,et al.  Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial. , 2017, Journal of the American College of Cardiology.

[12]  E. Malchiodi,et al.  Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against Trypanosoma cruzi , 2017, PLoS neglected tropical diseases.

[13]  R. Tarleton,et al.  Long-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant trans-Sialidase-Specific CD8+ T Cells , 2016, Infection and Immunity.

[14]  E. Malchiodi,et al.  A prime-boost immunization with Tc52 N-terminal domain DNA and the recombinant protein expressed in Pichia pastoris protects against Trypanosoma cruzi infection. , 2016, Vaccine.

[15]  P. Hotez,et al.  Status of vaccine research and development of vaccines for Chagas disease. , 2016, Vaccine.

[16]  D. Hoft,et al.  Th17 Cells Are More Protective Than Th1 Cells Against the Intracellular Parasite Trypanosoma cruzi , 2016, PLoS pathogens.

[17]  C. Buscaglia,et al.  Sialic Acid Glycobiology Unveils Trypanosoma cruzi Trypomastigote Membrane Physiology , 2016, PLoS pathogens.

[18]  P. Hotez,et al.  A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease , 2016, Human vaccines & immunotherapeutics.

[19]  E. Malchiodi,et al.  Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection , 2016, Human vaccines & immunotherapeutics.

[20]  N. Garg,et al.  Therapeutic Efficacy of a Subunit Vaccine in Controlling Chronic Trypanosoma cruzi Infection and Chagas Disease Is Enhanced by Glutathione Peroxidase Over-Expression , 2015, PloS one.

[21]  A. Carabarin-Lima,et al.  Experimental Vaccines against Chagas Disease: A Journey through History , 2015, Journal of immunology research.

[22]  N. Garg,et al.  A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity against Trypanosoma cruzi , 2015, PLoS pathogens.

[23]  R. Tarleton.  CD8+ T cells in Trypanosoma cruzi infection , 2015, Seminars in Immunopathology.

[24]  R. Tarleton,et al.  Reaching for the Holy Grail: insights from infection/cure models on the prospects for vaccines for Trypanosoma cruzi infection , 2015, Memorias do Instituto Oswaldo Cruz.

[25]  Arturo Ferreira,et al.  Gene-deleted live-attenuated Trypanosoma cruzi parasites as vaccines to protect against Chagas disease , 2015, Expert review of vaccines.

[26]  N. Callewaert,et al.  Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease. , 2015, Vaccine.

[27]  E. Malchiodi,et al.  Oral multicomponent DNA vaccine delivered by attenuated Salmonella elicited immunoprotection against American trypanosomiasis. , 2015, The Journal of infectious diseases.

[28]  D. Moore,et al.  Prevalence of Chagas Disease in Latin-American Migrants Living in Europe: A Systematic Review and Meta-analysis , 2015, PLoS neglected tropical diseases.

[29]  R. Gazzinelli,et al.  A Human Type 5 Adenovirus-Based Trypanosoma cruzi Therapeutic Vaccine Re-programs Immune Response and Reverses Chronic Cardiomyopathy , 2015, PLoS pathogens.

[30]  E. Malchiodi,et al.  Tc52 Amino-Terminal-Domain DNA Carried by Attenuated Salmonella enterica Serovar Typhimurium Induces Protection against a Trypanosoma cruzi Lethal Challenge , 2014, Infection and Immunity.

[31]  C. Murray,et al.  The Global Burden of Disease Study 2010: Interpretation and Implications for the Neglected Tropical Diseases , 2014, PLoS neglected tropical diseases.

[32]  M. Bonneville.  Human ?d T cell responses to infections and cancer: From basic immunology to immunotherapy , 2013 .

[33]  D. C. Cara,et al.  Vaccination Using Recombinants Influenza and Adenoviruses Encoding Amastigote Surface Protein-2 Are Highly Effective on Protection against Trypanosoma cruzi Infection , 2013, PloS one.

[34]  D. Liggitt,et al.  Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORγt and Ahr that leads to IL-17 production by activated B cells , 2013, Nature Immunology.

[35]  P. Hotez,et al.  Global economic burden of Chagas disease: a computational simulation model. , 2013, The Lancet. Infectious diseases.

[36]  R. Galler,et al.  Recombinant Yellow Fever Viruses Elicit CD8+ T Cell Responses and Protective Immunity against Trypanosoma cruzi , 2013, PloS one.

[37]  S. Schenkman,et al.  T rypanosoma cruzi trans‐sialidase as a multifunctional enzyme in Chagas’ disease , 2012, Cellular microbiology.

[38]  P. Hotez,et al.  Modeling the economic value of a Chagas’ disease therapeutic vaccine , 2012, Human vaccines & immunotherapeutics.

[39]  H. Cejas,et al.  IL-17RA Signaling Reduces Inflammation and Mortality during Trypanosoma cruzi Infection by Recruiting Suppressive IL-10-Producing Neutrophils , 2012, PLoS pathogens.

[40]  C. Guzmán,et al.  NKT Cell Stimulation with α-Galactosylceramide Results in a Block of Th17 Differentiation after Intranasal Immunization in Mice , 2012, PloS one.

[41]  S. Montgomery,et al.  Trypanosoma cruzi and Chagas' Disease in the United States , 2011, Clinical Microbiology Reviews.

[42]  R. Gazzinelli,et al.  Subdominant/Cryptic CD8 T Cell Epitopes Contribute to Resistance against Experimental Infection with a Human Protozoan Parasite , 2011, PloS one.

[43]  R. Galler,et al.  Biological and immunological characterization of recombinant Yellow Fever 17D Viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome , 2011, Virology Journal.

[44]  M. Rodrigues,et al.  Co-Administration of a Plasmid DNA Encoding IL-15 Improves Long-Term Protection of a Genetic Vaccine against Trypanosoma cruzi , 2011, PLoS neglected tropical diseases.

[45]  R. Gazzinelli,et al.  Heterologous Plasmid DNA Prime-Recombinant Human Adenovirus 5 Boost Vaccination Generates a Stable Pool of Protective Long-Lived CD8+ T Effector Memory Cells Specific for a Human Parasite, Trypanosoma cruzi , 2011, Infection and Immunity.

[46]  Bruce Y. Lee,et al.  The Potential Economic Value of a Trypanosoma cruzi (Chagas Disease) Vaccine in Latin America , 2010, PLoS neglected tropical diseases.

[47]  E. Dumonteil,et al.  Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells. , 2010, Vaccine.

[48]  R. Tarleton,et al.  CD8+ T Cells Specific for Immunodominant Trans-Sialidase Epitopes Contribute to Control of Trypanosoma cruzi Infection but Are Not Required for Resistance , 2010, The Journal of Immunology.

[49]  Z. Yadón,et al.  Chagas disease: a Latin American health problem becoming a world health problem. , 2010, Acta tropica.

[50]  E. Malchiodi,et al.  Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection. , 2010, The Journal of infectious diseases.

[51]  L. Conteh,et al.  Socioeconomic aspects of neglected tropical diseases , 2010, The Lancet.

[52]  D. Hoft,et al.  Intranasal Vaccinations with the trans-Sialidase Antigen plus CpG Adjuvant Induce Mucosal Immunity Protective against Conjunctival Trypanosoma cruzi Challenges , 2010, Infection and Immunity.

[53]  V. Duschak,et al.  Cruzipain, the major cysteine protease of Trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. A review. , 2009, Current medicinal chemistry.

[54]  R. Tarleton,et al.  Insufficient TLR Activation Contributes to the Slow Development of CD8+ T Cell Responses in Trypanosoma cruzi Infection1 , 2009, The Journal of Immunology.

[55]  M. A. Basombrío,et al.  Protective immunity against Trypanosoma cruzi. , 2009, Memorias do Instituto Oswaldo Cruz.

[56]  N. Garg,et al.  Previously Unrecognized Vaccine Candidates Control Trypanosoma cruzi Infection and Immunopathology in Mice , 2008, Clinical and Vaccine Immunology.

[57]  E. Malchiodi,et al.  Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model. , 2008, Vaccine.

[58]  M. Rodrigues,et al.  Trans-Sialidase Recombinant Protein Mixed with CpG Motif-Containing Oligodeoxynucleotide Induces Protective Mucosal and Systemic Trypanosoma cruzi Immunity Involving CD8+ CTL and B Cell-Mediated Cross-Priming1 , 2007, The Journal of Immunology.

[59]  E. Malchiodi,et al.  Oral Vaccination with Salmonella enterica as a Cruzipain-DNA Delivery System Confers Protective Immunity against Trypanosoma cruzi , 2007, Infection and Immunity.

[60]  H. Volk,et al.  Interleukin-10 enhances the CD14-dependent phagocytosis of bacteria and apoptotic cells by human monocytes. , 2007, Human immunology.

[61]  E. Dumonteil,et al.  Comparative evaluation of therapeutic DNA vaccines against Trypanosoma cruzi in mice. , 2007, FEMS immunology and medical microbiology.

[62]  R. Gazzinelli,et al.  Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. , 2006, Human gene therapy.

[63]  R. Gazzinelli,et al.  CD8+-T-Cell-Dependent Control of Trypanosoma cruzi Infection in a Highly Susceptible Mouse Strain after Immunization with Recombinant Proteins Based on Amastigote Surface Protein 2 , 2005, Infection and Immunity.

[64]  B. Maigret,et al.  Molecular, functional and structural properties of the prolyl oligopeptidase of Trypanosoma cruzi (POP Tc80), which is required for parasite entry into mammalian cells. , 2005, The Biochemical journal.

[65]  J. Scharfstein,et al.  Chagasin, the endogenous cysteine-protease inhibitor of Trypanosoma cruzi, modulates parasite differentiation and invasion of mammalian cells , 2005, Journal of Cell Science.

[66]  F. Marincola,et al.  IL-10 stimulatory effects on human NK cells explored by gene profile analysis , 2004, Genes and Immunity.

[67]  M. Sinha,et al.  Utility of the Trypanosoma cruzi Sequence Database for Identification of Potential Vaccine Candidates by In Silico and In Vitro Screening , 2004, Infection and Immunity.

[68]  R. Gazzinelli,et al.  Protective immunity against trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase. , 2004, Human gene therapy.

[69]  E. Malchiodi,et al.  Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. , 2003, Vaccine.

[70]  S. Boscardin,et al.  A DNA‐priming protein‐boosting regimen significantly improves type 1 immune response but not protective immunity to Trypanosoma cruzi infection in a highly susceptible mouse strain , 2003, Immunology and cell biology.

[71]  R. Curtiss,et al.  Cruzipain Induces Both Mucosal and Systemic Protection against Trypanosoma cruzi in Mice , 2002, Infection and Immunity.

[72]  G. Caron,et al.  The Trypanosoma cruzi Tc52-Released Protein Induces Human Dendritic Cell Maturation, Signals Via Toll-Like Receptor 2, and Confers Protection Against Lethal Infection1 , 2002, The Journal of Immunology.

[73]  E. Davioud‐Charvet,et al.  Trypanosoma cruzi Prolyl Oligopeptidase Tc80 Is Involved in Nonphagocytic Mammalian Cell Invasion by Trypomastigotes* , 2001, The Journal of Biological Chemistry.

[74]  J. Scharfstein,et al.  Identification, characterization and localization of chagasin, a tight-binding cysteine protease inhibitor in Trypanosoma cruzi. , 2001, Journal of cell science.

[75]  A. Ouaissi,et al.  Intracellular growth and metacyclogenesis defects in Trypanosoma cruzi carrying a targeted deletion of a Tc52 protein‐encoding allele , 1999, Molecular microbiology.

[76]  S. Schenkman,et al.  Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice. , 1998, Vaccine.

[77]  J. Cazzulo,et al.  Membrane-bound cysteine proteinase isoforms in different developmental stages of Trypanosoma cruzi. , 1998, Cellular and molecular biology.

[78]  R. Tarleton,et al.  Amastigote surface proteins of Trypanosoma cruzi are targets for CD8+ CTL. , 1998, Journal of immunology.

[79]  C. Harding,et al.  CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity , 1997, The Journal of experimental medicine.

[80]  D. Richman,et al.  Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants , 1997, Nature Medicine.

[81]  A. Teixeira,et al.  A Trypanosoma cruzi-secreted 80 kDa proteinase with specificity for human collagen types I and IV. , 1997, The Biochemical journal.

[82]  T. Slifer,et al.  IL-10 is required to prevent immune hyperactivity during infection with Trypanosoma cruzi. , 1997, Journal of immunology.

[83]  G. Bishop,et al.  CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.

[84]  A. Frasch,et al.  Mice infected with Trypanosoma cruzi produce antibodies against the enzymatic domain of trans-sialidase that inhibit its activity , 1994, Infection and immunity.

[85]  C. Figdor,et al.  IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10. , 1992, Journal of immunology.

[86]  M. Pereira,et al.  Mapping of a B-cell epitope present in the neuraminidase of Trypanosoma cruzi. , 1992, Molecular and biochemical parasitology.

[87]  J. Banchereau,et al.  Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[88]  A. Frasch,et al.  The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is encoded by multiple polymorphic tandemly organized genes located on different chromosomes. , 1992, Molecular and biochemical parasitology.

[89]  E. Malchiodi,et al.  Isolation of a Trypanosoma cruzi antigen by affinity chromatography with a monoclonal antibody. Preliminary evaluation of its possible applications in serological tests , 1990, Clinical and experimental immunology.

[90]  A. Frasch,et al.  Fetal IgG specificities against Trypanosoma cruzi antigens in infected newborns. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[91]  E. Malchiodi,et al.  Attenuated Salmonella sp. as a DNA Delivery System for Trypanosoma cruzi Antigens. , 2016, Methods in molecular biology.

[92]  Global, regional, and national incidence, prevalence, and YLDs for 301 acute and chronic diseases and injuries for 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015 .

[93]  Rino Rappuoli,et al.  Reverse vaccinology. , 2000, Current opinion in microbiology.

[94]  A. Ouaissi,et al.  Trypanosoma cruzi cDNA encodes a tandemly repeated domain structure characteristic of small stress proteins and glutathione S‐transferases , 1994, Biology of the cell.